Cytochrome P450 mono-oxygenases (P450s) are the principal enzymes involved in the oxidative metabolism of drugs and other xenobiotics. In this protocol, we describe a fluorescence-based, high-throughput assay for measuring the activity of P450 3A4, one of the key enzymes involved in drug metabolism. The assay involves the oxidative debenzylation of a substituted coumarin, yielding an increase in fluorescence on reaction. The entire procedure can be accomplished in 1 h or less.
INTRODUCTION
Cytochrome P450 (P450) mono-oxygenases are heme-thiolate proteins that are found in almost all living organisms. In addition to the biosynthesis of essential endogenous molecules, such as steroids and eicosanoids, they are also responsible for the oxidative metabolism of a wide variety of xenobiotics 1, 2 . In all, 57 genes are found in humans, but five of the P450 enzymes-1A2, 2C9, 2C19, 2D6 and 3A4-are responsible for 490% of metabolism of drugs currently in clinical use [2] [3] [4] . Considerable emphasis is placed on the role of these P450s in the pharmaceutical industry, in terms of assays for contributions to metabolism of new chemical entities and enzyme inhibition.
Various in vitro assays for measuring the activity and inhibition of P450s have been developed over the years 5 . The most commonly applied method today is to use recombinant P450s with probe substrates, with the resulting products resolved by high-performance liquid chromatography (HPLC) and detected by a mass spectrometer (MS) coupled to the HPLC system [6] [7] [8] . These HPLC-MS based assays are highly sensitive and have been used as an industry standard method for P450 inhibition assessments. However, this method cannot be fit into a high-throughput format and may be problematic when large numbers of samples need to be tested (e.g., profiling the inhibitory potential of a chemical library against a specific P450 oxygenase). In this situation, fluorescence-based P450 assays are much faster and more cost effective than HPLC-MS assays 9, 10 . In these assays, P450 oxidizes a pro-fluorescent molecule to a fluorescent product. This product can be directly measured using a fluorescence microplate reader. However, all fluorescence measurements must be cautiously monitored for fluorescence interference or fluorescence quenching from tested compounds. In principle such assays can be carried out whenever the fluorescence of a reaction product is sufficient to be detected accurately. Examples include our work with P450 1A2 and resorufins 11 and P450 2A6 and coumarin 7-hydroxylation 12 .
In this protocol, we present a microtiter plate-based fluorescence assay for the activity of P450 3A4. A number of coumarins and other fluorophores have been used in P450 fluorescence assays [13] [14] [15] . 7-Benzoyloxy-4-trifluoromethyl coumarin (BFC) is used in this assay as the probe substrate and undergoes O-dealkylation to give the fluorescent product 7-hydroxy-4-trifluoromethyl coumarin (HFC, l excitation 405 nm/l emission 510-545 nm) (Fig. 1) 15 . In this protocol, we demonstrate how this assay can be applied in the determination of the IC 50 value of ketoconazole, a potent inhibitor of P450 3A4.
The literature contains fluorescent reactions that can be used with other P450s [11] [12] [13] [14] [15] . Another alternative for high-throughput P450 activity assays is luminescence methods. Analogous to the fluorescence assays, a pro-luminescent substrate is used and yields a product that emits luminescence upon the addition of a developing agent 16 . The advantage of luminescence assays is the improved signal-to-noise ratio compared with fluorescence. The major drawback is that an additional development step is needed and the signal cannot be monitored in a continuous mode.
Experimental design
The protocol can be applied to directly determine IC 50 values for compounds that are potential P450 3A4 inhibitors. Recombinant P450 3A4 protein without other P450s is recommended in this assay, because other P450s, e.g., 1A2, can also transform BFC to HFC. The compounds to be studied should be dissolved in water if they are soluble. Otherwise, prepare the compounds in acetonitrile or methanol. Adjust the concentration of the inhibitor so that the organic solvent is o 1% (vol/vol) in the final reaction to avoid interference with P450 catalytic activities. The plate setup used in this protocol is described in Table 1 . The reaction is carried out in duplicate in rows A and B. Varying amounts of ketoconazole are added to the wells (columns 1 through 10). Well 11 serves as the blank control, because the stopping buffer is added before the addition of the NADPH-regenerating system. The fraction of activity remaining with inactivated P450 3A4 (obtained in the presence of ketoconazole) compared with the activity in the absence of any added compound to the reaction mixture (column 12, control, absence of P450 3A4 inhibition) is used in the calculations. The ratio of inactivated P450 is plotted as a function of ketoconazole concentration using a 4-parameter logistic equation: y ¼ a + ðb À aÞ=ð1 + 10 ðxÀcÞd Þ) using the software available at http://www.changbioscience.com/stat/ec50.html. 
REAGENT SETUP
Water for all buffers and incubations should be purified using a Milli-Q (Millipore, Billerica, MA, USA) system.
. NADPH-generating system: combine 50 parts 10 mM NADP + , 50 parts 0.1 M glucose-6-phosphate and 1 part 1 mg ml À1 yeast glucose-6-phosphate dehydrogenase; prepare fresh daily; store on ice when not in use.
. 10 mM NADP + : 382 mg in 50 ml of (Milli-Q) water, remains stable for several months if it is stored at 4 1C.
. 0.1 M glucose-6-phosphate: 3.4 g in 100 ml of (Milli-Q) water, remains stable for several months if it is stored frozen at À20 1C.
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PROCEDURE
Plate setup TIMING 30 min 1| Dispense 0.06 ml of 0.1 M potassium phosphate buffer into each of the wells (columns 2-12) of a 96-well plate using a multichannel pipette.
2| Dispense 0.118 ml of 0.1 M potassium phosphate buffer and 0.002 ml of 1 mM ketoconazole into the wells in column 1.
3| Serially dilute 0.06 ml from the well (in column 1) to the other wells (columns 2-10). Remove the extra 0.06 ml in the well in column 10.
4| Dispense 0.1 ml of 2Â enzyme-substrate mix in all the wells. Add 0.075 ml of stop buffer to the wells in column 11.
5|
Incubate the plate in a 37 1C incubator for 5 min.
6| Remove the plate from the incubator and dispense 0.04 ml of NADPH-generating system into each well to initiate the reaction.
Plate incubation TIMING 20 min 7| Incubate the plate for 15 min in a 37 1C incubator, and then add 0.075 ml of stop buffer to each well (except wells in column 11).
IC 50 calculation TIMING 20 min 8| Scan the plate using the Polarstar plate reader, average the replicates of data for each column. Table 2 .
ANTICIPATED RESULTS
Fluorescence readings from dealkylation of BFC by P450 3A4 and the data processing are shown in Table 3 . Background fluorescence reading is shown in well 11, where the NADPH-generating system is added after the addition of stop buffer. The 100% enzyme activity value is obtained in well 12, where no inhibitor was added. Sometimes low signal/noise ratios (well 12/well 11o 2) can be problematic. This is often caused by decreased P450 activities and can normally be corrected by increasing the enzyme concentration. The IC 50 determined by the 4-parameter logistic fitting was 54 nM, using the webbased program (Fig. 2) . 
